Diet / Gut Microbiome Interaction and Influence on Inflammatory Disease in HIV Patients

NCT ID: NCT02610374

Last Updated: 2022-01-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-31

Study Completion Date

2020-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to assess the effect of short-term diet modification on the microbiome composition, and inflammatory/metabolic disease markers in Antiretroviral therapy (ART)-treated HIV-infected participants and Human immunodeficiency virus (HIV)-negative controls in the United States.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized clinical trial. Fifty (50) Antiretroviral therapy (ART)-treated Human immunodeficiency virus (HIV) positive participants, 24 HIV negative controls matched for age and sex, and 24 HIV negative controls from a population at high risk for contracting HIV will be recruited into 3 cohorts. All participants will undergo a 4 week diet modification and will be randomly assigned to receive either an Agrarian diet or a Western-type diet. For the first 2 weeks, food will be provided to the participant, followed by an additional 2 weeks where participants will be provided a diet menu with recipes to prepare themselves. There will be 4 study visits and participation will last for up to 2 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort A

HIV-positive individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.

Group Type OTHER

Agrarian Diet

Intervention Type OTHER

A diet higher in carbohydrates and lower in fats and sugars

Western-type Diet

Intervention Type OTHER

A diet higher in fats and lower in carbohydrates

Cohort B

HIV-negative high-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.

Group Type OTHER

Agrarian Diet

Intervention Type OTHER

A diet higher in carbohydrates and lower in fats and sugars

Western-type Diet

Intervention Type OTHER

A diet higher in fats and lower in carbohydrates

Cohort C

HIV-negative low-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.

Group Type OTHER

Agrarian Diet

Intervention Type OTHER

A diet higher in carbohydrates and lower in fats and sugars

Western-type Diet

Intervention Type OTHER

A diet higher in fats and lower in carbohydrates

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Agrarian Diet

A diet higher in carbohydrates and lower in fats and sugars

Intervention Type OTHER

Western-type Diet

A diet higher in fats and lower in carbohydrates

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV-infected cohort (Cohort A)

* Documentation of HIV-1 infection defined as a positive antibody test or plasma HIV-1 RNA (ribosomal ribonucleic acid).
* Treated with ART (minimum of three antiretroviral drugs in regimen) for at least 12 months with no changes in antiretroviral drugs over the past 6 months
* Plasma HIV-1 RNA ≤ 50 copies/mL in the preceding 6 months.
* HIV-negative cohorts (Cohort B and C)

* Documentation of a negative HIV-1 antibody test
* All Cohorts

* Age 18 to 65 years
* Body mass index between 21-29 kg/m2 (non-obese)
* Stable weight for at least 3 months (≤15% change in body weight)
* Negative pregnancy test (if female)

Exclusion Criteria

* Use of systemic (oral or parenteral) antibiotics within two months prior to study entry
* Active chronic infection such as hepatitis B or C or an active malignancy that requires systemic chemotherapy.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Colorado, Denver

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Catherine Lozupone, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Colorado Denver

Aurora, Colorado, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

15-1692

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

COVID-19 in Patients With HIV
NCT04333953 COMPLETED
The Biology of HIV Transmission
NCT00001092 COMPLETED